**ORIGINAL ARTICLE**

10 kHz Spinal Cord Stimulation for the Treatment of Failed Back Surgery Syndrome with Predominant Leg Pain: Results from a Prospective Study in Patients from the Dutch Healthcare System

Jan Willem Kallewaard*, MD phd; Ismail Gültuna, MD†; Vincent Hoffmann, MD‡; Lars Elzinga, MD§; Renate Munnikes, MD¶; Lisette Verbrugge, MD¶; Veerle Minne, MSc**; Pascalle Reiters, MSc**; Jeyakumar Subbaroyan, PhD**; Angela Santos, MSc**; Anand Rotte, PhD**; David Caraway, MD, PhD**

*Rijnstate Ziekenhuis Velp, Pijncentrum, Pijnbehandelcentrum, Velp; †Albert Schweitzer Ziekenhuis, Pijnbehandelcentrum, Zwijndrecht; ‡Amphia Ziekenhuis Breda Pijnbehandelcentrum, Breda; §Bravis Ziekenhuis Roosendaal, Pijncentrum, Roosendaal; ¶Maasstad Ziekenhuis Rotterdam, Pijnkliniek, Rotterdam, The Netherlands; **Nevro Corp., Redwood City, California U.S.A.

** Abstract **

*Introduction:* Persistent back/and or leg pain is a common outcome after spinal surgery (otherwise known as failed back surgery syndrome [FBSS]). Studies have shown that spinal cord stimulation (SCS) at 10 kHz provides effective analgesia in FBSS patients with both back and leg pain symptoms and in those with predominant back pain. This study is the first to evaluate the therapy in FBSS patients with predominant leg pain.

*Methods:* The safety and efficacy of 10 kHz SCS was evaluated in an uncontrolled, open-label, prospective study of FBSS patients with predominant leg pain in the Netherlands. Follow-ups were performed at 1, 3, 6, and 12 months post implantation.

*Results:* Sixty out of 68 patients (88%) experienced sufficient pain relief during a stimulation trial. Of these, 58 proceeded to permanent implantation of a 10 kHz SCS system. After 12 months of treatment, 80% of patients experienced ≥50% reduction in baseline leg pain, and a similar proportion (76%) experienced ≥50% reduction in baseline back pain. At least two-thirds of patients were also leg pain and back pain remitters (visual analog scale [VAS])
The therapy was also associated with a general improvement in patients’ quality of life, as measured by secondary outcomes including disability, perception of health improvement, mental well-being, and satisfaction. A positive impact on opioid consumption was also observed. **Conclusions:** Consistent with previous findings, 10 kHz SCS for the treatment of FBSS patients with predominant radicular symptoms is safe and effective and is associated with improved quality of life.

**Key Words:** 10 kHz SCS, failed back surgery syndrome, leg pain and VAS

**INTRODUCTION**

Low back pain is a common health complaint that has risen in prevalence during recent decades. During the same time frame, the rate of spinal surgery has also increased in developed countries. While many patients benefit from surgical intervention, recent studies suggest that around one in five patients experience persistent back and/or leg pain after surgery (otherwise known as failed back surgery syndrome [FBSS]). The prevalence of FBSS among the general population is estimated to be on par with more recognized chronic pain conditions such as rheumatoid arthritis (around 0.5% to 0.6%).

Traditional spinal cord stimulation (SCS) is a minimally invasive therapy that has been widely used in recent decades to treat FBSS. During traditional SCS, low-frequency (up to 200 Hz) electrical pulses delivered to the spinal cord elicit paresthesia over the painful area to mask the sensation of pain. Two randomized controlled trials (RCTs) have confirmed the analgesic efficacy of the therapy in FBSS patients with predominant leg pain. North and colleagues randomized patients to either reoperation or traditional SCS. After 3 years, the study found that traditional SCS provided more effective pain relief than reoperation. In the PROCESS RCT, patients received either traditional SCS and conventional medical management (CMM) or CMM alone. Over 24 months, the traditional SCS + CMM group reported improved pain relief, quality of life, and functional outcomes compared with the CMM group.

Various European bodies have assessed the evidence base for SCS in FBSS. The European Federation of Neurological Societies (EFNS) review concluded that the therapy is efficacious in this population with grade B supporting evidence. In the U.K., the National Institute for Health and Clinical Excellence (NICE) recommended the therapy as a cost-effective treatment option for FBSS (either as an alternative to further lumbar surgery or as an adjunct to CMM). A recent systematic review by the Zorginstituut Nederland (ZIN) showed moderate evidence for neuromodulation in FBSS patients with predominant leg pain. Reimbursement in the Netherlands is strictly dependent on the ZIN guidelines.

Ten kilohertz SCS, an alternative paresthesia-free SCS paradigm, has emerged to address the concerns with paresthesia coverage and lack of effective pain relief in significant proportion of patients. In an RCT, 10 kHz SCS demonstrated clinical benefit in patients with both back and leg pain. The SENZA-RCT mainly comprised FBSS patients (87%) with baseline back pain and leg pain of at least 5 cm on the visual analog scale (VAS). The study demonstrated that 10 kHz SCS resulted in significant and sustained decrease in both back pain and leg pain up to 24 months. Moreover, pain relief was superior to traditional SCS and was associated with improved quality of life and functional capacity. Among the 10 kHz SCS group, the absence of paresthesia and stimulation-related discomfort were additional advantages over traditional SCS. While 10 kHz SCS has demonstrated analgesic efficacy in FBSS patients with both back and leg pain and in those with predominant back pain in multiple studies in addition to the RCT, the evidence is limited in FBSS patients with predominant radicular symptoms. Additional postmarket studies are required to confirm the benefits of the therapy in this population. Therefore, the present study aimed to evaluate the efficacy of 10 kHz SCS in a Dutch population of FBSS patients with predominant leg pain.

**METHODS**

**Study Design and Participants**

This prospective, multicenter, open-label study was conducted in five sites throughout the Netherlands. Non-WMO (Medical Research Involving Human Subjects Act, The Netherlands) research and local ethics committee approvals were obtained at each participating site as required. The study was performed in accordance with ISO 14155-2011; Data Protection Directive 95/46/EC; recommendations guiding physicians in biomedical research involving humans adopted by the 18th World Medical Assembly, Helsinki, Finland (1964 and later revisions); and local laws and regulations.
Patients aged 18 years or over who had provided written informed consent were screened for enrolment according to the following key eligibility criteria: diagnosed with FBSS refractory to conservative therapy and minimally invasive pain procedures for at least 3 months and indicated as per Dutch SCS guidelines, average leg pain intensity ≥ 5 out of 10 cm on the VAS, and back pain intensity ≤ average leg pain intensity on the VAS (Table 1). Patients had also undergone a minimum of one evaluation at the investigational site prior to screening, were appropriate candidates for the required surgical procedures, had a stable pain medication regime for at least 4 weeks prior to the baseline visit, could use the study equipment, and were able to comply with study-related procedures.

Major exclusion criteria included pain in one or more areas, not intended to be treated with SCS, that could confound the evaluation of study endpoints; radiographic evidence of mechanical spinal instability requiring fusion; and pain significantly exacerbated by activity or alleviated by rest (Table 1). Patients were also excluded from participation if they had visceral pain in the area being treated (non-neuropathic pain), had benefited within 30 days prior to enrolment from an interventional procedure and/or surgery to treat back and/or leg pain, had prior experience with SCS, or were not appropriate candidates for the surgical procedures or SCS therapy. Patients with evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome, as determined by psychological evaluation prior to the trial; patients with coagulation disorders; and pregnant patients were excluded from the study.

Procedures

Eligible patients proceeded to a baseline visit followed by a temporary trial of 10 kHz SCS lasting 7 to 21 days. Each site performed the trial and implant procedure according to their usual clinical practice and following manufacturer guidelines. If no anatomical limitations were encountered, patients were implanted with two percutaneous leads staggered between the T8 and T11 vertebral levels (Figure 1A). The implanted leads were subsequently connected to a temporary external stimulation device. Impedance measurements and fluoroscopy were used to verify lead location and function. Anterior-posterior and lateral x-rays were also taken to confirm the final position of the leads. During the trial phase, patients received 10 kHz, 30 μs stimulation with amplitudes between 0 and 5 mA, testing outwards from the T9/T10 vertebral level until programming settings were found that provided best pain relief. Trial leads remained implanted at the end of trial period in patients who experienced ≥ 50% reduction in baseline leg pain (permanent trials). The trial stimulator was collected at the end of the trial period, and the patients either proceeded to permanent implant on the same day or were scheduled to receive a permanent implant of a 10-kHz SCS system (Senza™ system; Nevro Corp, Redwood City, CA, U.S.A.) within 14 days. The permanent device was programmed with the optimal stimulation parameters determined during the trial phase. While detailed information on sweet spots and contacts for stimulation was not collected during the study, most patients were stimulated between mid-T9 to mid-T10 using the X-rays taken at the time of the implant.

Outcomes

Outcomes were collected at baseline and 1, 3, 6, and 12 months after permanent implantation (Figure 1B). The primary outcome measure was the responder rate at 12 months, with response defined as ≥ 50% reduction in leg pain from baseline measured on the VAS.

Secondary outcomes included responder rate prior to 12 months; the proportion of patients reporting ≥ 50% reduction in baseline back pain measured on the VAS; changes in baseline pain intensity recorded on the VAS; functional disability reported on the Oswestry Disability Index (ODI); impression of change in health evaluated using the Global Impression of Change (GIC) questionnaires for clinicians and patients; catastrophic thinking
related to pain measured using the Pain Catastrophizing Scale (PCS); emotional mood status measured on the Hospital Anxiety and Depression Scale (HADS); and patient satisfaction. Medication usage and change in opioid dose following treatment were not the endpoints of the study but were collected and reported for all patients on opioids during the study.

Statistics
Descriptive statistics were used to summarize data collected during the study. Continuous variables were summarized using the number of observations (patients), mean, standard error of the mean (SEM), minimum, median, and maximum. Categorical variables were summarized using counts and percentages. As this was a noncomparative study, the sample size was computed to reach a prespecified precision of 60% to 65% for the responder rate at 12 months, and calculated using the confidence interval formula, based on the Clopper–Pearson method. Analysis of effectiveness-related endpoints was conducted on patients who completed each study visit. All analyses were carried out in Microsoft Excel.

RESULTS
Demographics
Between April 2015 and September 2017, 70 patients were enrolled in the study (Figure 1B). The last study visit occurred in October 2018. The demographics and baseline characteristics of the enrolled patients are detailed in Table 2. Overall, patients had experienced FBSS symptoms for 2.3 years. Around half of the cohort experienced unilateral leg pain (vs. bilateral leg pain).
The majority (90%) were diagnosed with intractable back and leg pain (Table 2); however, the inclusion criteria required patients to have leg pain greater than or equal to back pain at the time of enrolment, and the mean VAS score for leg pain (7.7 cm) was higher than the back pain (5.5 cm) at baseline.

### Trial Phase

All 70 enrolled patients underwent a temporary stimulation trial; however, two patients experienced an adverse event during the trial phase and were excluded. Of the 68 remaining patients that completed the trial, 60 (88%) experienced a reduction of at least 50% in baseline leg pain. A further two patients were excluded after the trial phase: one due to an adverse event and one due to physician decision. In total, 58 patients proceeded to receive a permanent implant.

### Longitudinal Leg and Back Pain

Mean leg pain VAS score (±SD) decreased from 7.7 ± 2.4 cm at baseline to 1.2 ± 2.0 cm at the end of the trial, an average reduction of 84%. A high level of leg pain relief was sustained for 12 months, with average decreases in baseline VAS score of 76%, 70%, 58%, and 75% at 1, 3, 6, and 12 months, respectively (Figure 2A).

Likewise, a high level of back pain relief was experienced during the trial phase and maintained out to 12 months (Figure 2A). Mean back pain (±SD) decreased from 5.6 ± 1.0 cm at baseline to 1.2 ± 1.6 cm at the end of the trial, an average reduction of 73%. The respective average decreases in back pain VAS score at 1, 3, 6, and 12 months were 52%, 58%, 53%, and 63%, respectively.

### Responder and Remitter Rates

At 12 months, 80% of patients (N = 40/50) were responders to therapy for leg pain (Figure 2B). A similar proportion (76%, N = 38/50) reported response for back pain (Figure 2B). In both pain regions, at least 60% of patients reported ≥ 50% pain relief throughout follow-up.

Patients were classified as remitters if they achieved a VAS score of ≤ 2.5 cm. At 12 months, 68% (N = 34/50) and 80% (N = 40/50) of patients were leg pain and back pain remitters, respectively (Figure 2C). In both pain regions, a high proportion of patients were
remitters during the follow-up period (at least 48% for leg pain and 59% for back pain).

Quality of Life
On the GIC questionnaires collected after 12 months of treatment, 80% of patients were rated by their clinician as “very much” or “much” improved, and 72% of patients reported feeling “very much” or “much” improved (Figure 3A,B). At 12 months, 86% of the cohort indicated that they were “very satisfied” or “satisfied” with their therapy (Figure 3C).

Functional outcomes on the ODI are shown in Figure 4. Patients’ overall level of disability, measured using the mean ODI score, decreased from 52.4 ± 1.6 at baseline to 33.3 ± 2.5 after 1 month of treatment, an average reduction of 19.1 ± 2.0 points. After 6 and 12 months of treatment, the average decreases in ODI score were 19.7 ± 2.3 and 25.3 ± 2.3 points, respectively. Disability categorization was also evaluated according to ODI score at baseline and 12 months (minimal disability: 0 to 20; moderate disability: 21 to 40; severe disability: 41 to 60; crippled: 61 to 80; bedbound or exaggerating symptoms: 81 to 100). After 12 months of treatment, 62% of patients (N = 31/50) reduced their ODI score sufficiently to reclassify them from severely disabled or crippled to moderately or minimally disabled.

Opioid Usage and Mental Status
Patients were classified at baseline and 12 months according to their daily intake of oral morphine equivalent (none, PRN, 1 to 49 mg/day, 50 to 90 mg/day, or > 90 mg/day; Figure 5A). Twenty-nine out of 58 implanted patients were taking opioids at baseline or at 12 months. Of these, seven (24%) ceased intake, and a further two reduced their consumption (7%). The percentage of patients taking opioids at safe doses (none, PRN, or < 50 mg/day) increased to 80% at 12 months (Figure 5A).

Patients’ mental status, measured on the HADS scale, improved during the study compared with baseline (Figure 5B). The HADS anxiety subscale mean scores decreased from 6.0 ± 0.5 points at baseline by an average of 2.4 ± 0.3, 1.9 ± 0.4, and 2.2 ± 0.5 points after 1, 6, and 12 months of treatment, respectively. Likewise, the HADS depression subscale mean scores decreased from 6.9 ± 0.6 points at baseline by an average of 2.9 ± 0.4, 2.8 ± 0.4, and 3.2 ± 0.5 points after 1, 6, and 12 months of treatment, respectively.

A decrease in pain catastrophizing was also observed on the PCS at each follow-up. Mean global PCS score reduced from 22.9 ± 1.4 points at baseline to 14.5 ± 1.3, 12.7 ± 1.7, and 14.8 ± 1.7 points at 1, 6, and 12 months, respectively (Figure 5C). The decrease in total PCS score reflected consistent reductions vs. baseline in all three subscales of the PCS throughout follow-up (helplessness, magnification, and rumination).
Safety

No unanticipated adverse device effects (UADEs) occurred during the study at any point. A total of six serious adverse events (SAEs) were reported during the 12-month study period in five patients. All SAEs were resolved.

DISCUSSION

Failed back surgery syndrome is a complex and challenging pathology to treat. 10 kHz SCS is a minimally invasive intervention that provides paresthesia-free pain relief. The therapy is used to treat a variety of chronic pain etiologies associated with trunk and/or limb pain. To date, the evidence supporting the use of the therapy in FBSS patients is predicated on those diagnosed with either both back and leg pain or predominant back pain.

To our knowledge, this is the first study to evaluate 10 kHz SCS in FBSS patients with predominant radicular symptoms (Table 3). Among our cohort, the therapy provided substantial and robust leg pain relief without compromising back pain relief. Notably, at
least two-thirds of our patients also met the remitter criteria for leg pain and back pain. The therapy was safe and well tolerated, with no UADEs reported during the study.

Our 12-month pain relief outcomes are consistent with previous studies of the therapy that included FBSS patients with other pain patterns. The SENZA-RCT enrolled patients with both leg pain and back pain ≥ 5 cm on the VAS. In the 10 kHz SCS group, most patients (87%) had undergone previous spinal surgery, and average baseline leg pain and back pain VAS scores were 7.1 and 7.4 cm, respectively. The study reported responder rates in the 10 kHz SCS group of 79% in both pain areas at 12 months, along with an average decrease in mean baseline leg pain and back pain of 5.0 and 4.9 cm, respectively. Two-thirds of the group also achieved remitter status in leg pain and back pain (VAS ≤ 2.5 cm).

In the prospective, single-arm SENZA-EU study of 10 kHz SCS in predominant back pain, the majority of implanted patients had a history of spinal surgery (79%). Patients reported average baseline leg pain and back pain scores of 5.4 and 8.4 cm, respectively. At 12 months, 65% and 70% of the cohort were leg pain and back pain responders, respectively, while mean baseline leg pain and back pain decreased by an average

Table 3. Outcomes Reported in Prospective and Retrospective Studies Evaluating the Benefits of 10 kHz spinal cord stimulation (SCS) in failed back surgery syndrome (FBSS) Patients

| Study (Reference) | Total N, % of FBSS Patients | FU Period | Outcomes |
|-------------------|-----------------------------|-----------|----------|
| SENZA RCT³⁷-⁴⁹    | 90 (87%)                    | 24 months | Baseline vs. 24 months:  
Average back pain relief: 68%  
Average leg pain relief: 66%  
Responder rate back pain: 77%  
Responder rate leg pain: 73%  
ODI: Minimal to moderate category increased from 9% to 65%. Severe to crippled category decreased from 91% to 35%  
Satisfaction: 86%  
Patient rated GIC: 75%  
Clinician rated GIC: 78%  
Reduced/eliminated opioids: 36%* |
| Prospective, two-center study in Europe²¹ | 72 (79%) | 24 months | Baseline vs. 24 months:  
Average back pain relief: 61%  
Average leg pain relief: 57%  
Responder rate back pain: 60%  
Responder rate leg pain: 71%  
Average reduction in ODI score: 27%  
Satisfaction: 81%  
Average reduction in sleep disturbances at night: 62%  
Reduced/eliminated opioids: 72% |
| Single-center, prospective study²² | 21 (100%) | 12 months | Baseline vs. 12 months:  
Average pain relief: 54%  
Responder rate pain: 67%  
Reduced/eliminated opioids: 65% |
| Retrospective, multicenter, review²⁷ | 1660 (NR) | 12 months | At last follow-up:  
Average pain relief: 63%  
Responder rate: 74%  
Decreased medication: 32%  
Improvement in function: 72%  
Improvement in sleep: 68% |
| Single center retrospective study¹⁰ | 32 (NR) | 12 months | Baseline vs. 12 months:  
Average back pain relief: 46%  
Average leg pain relief: 51%  
Responder rate: not reported  
Reduced/eliminated opioids: 71%  
Reduction in interventional procedures: 72% |
| Single-center retrospective case series²³ | 99 (94%) | 12 months | Baseline vs. 12 months*:  
Average back pain relief: 53%  
Average leg pain relief: 53%  
Responder rate back pain: 56%  
Responder rate leg pain: 59%  
Patient rated GIC: 83% |

FBSS, failed back surgery syndrome; FU, follow-up; Global Impression of Change, GIC, NR, not reported; ODI, Oswestry Disability Index.

*12-month follow-up data. ¹N = 69 for patients with > 12 months follow-up. ²Satisfied or very satisfied. ³Moderately better, better, or a great deal better.
of 3.4 cm and 5.6 cm, respectively. A smaller, single-arm, prospective study of the therapy in FBSS patients with predominant back pain also reported a high responder rate after 12 months of treatment (67%), along with a decrease in average VAS score of 4.7 cm from a baseline mean of 8.7 cm.²²

Stauss and colleagues also evaluated 10 kHz SCS in a large, retrospective, real-world study of chronic back and leg pain patients.²⁷ Surgical history was not reported; however, as FBSS is the most common indication for SCS implantation,²⁸,²⁹ the cohort is likely to have included a high proportion of FBSS patients. The authors reported a combined responder rate of 78% for back and leg pain at 12 months, as well as a reduction in median pain intensity among the responder group of 5.0 points from a baseline median of 8.0 points (numerical rating scale).

Among chronic pain patients, pain relief is a critical measure of therapy effectiveness. However, the impact of a therapy on patients' lives beyond pain relief is also an important consideration. After 12 months of 10 kHz SCS, patients in the current study reduced their level of disability and reported a perceived improvement in health. Furthermore, a third of the patients that took opioids at some point during the study reduced or eliminated their intake. Previous studies of 10 kHz SCS in FBSS patients have documented similar benefits.¹⁹,²¹,²²,²²,²³,²⁷

In the SENZA-RCT, 70% of the 10 kHz SCS group reduced their ODI classification at 12 months, while quality of life in the cohort increased across various scales.¹⁹ In addition, 35% of patients reduced or eliminated their opioid intake. The SENZA-EU study found a functional improvement after 24 months, as well as reduced opioid consumption.¹¹ A smaller, single-arm, prospective study of the therapy in FBSS patients with predominant back pain also reported functional improvement and reduced opioid intake after 12 months.²² In the large, retrospective study by Stauss et al.,²⁷ a high proportion of the cohort indicated improved function (72%) and quality of life (90%), and a third of the cohort reduced their medication intake.

Some of the wider benefits of 10 kHz SCS in our cohort are further reflected in their improved mental well-being. Average anxiety and depression scores both decreased on the HADS scale, and pain catastrophizing reduced on the PCS. These outcomes may be important because affective aspects such as depression, anxiety, and catastrophizing are often associated with elevated levels of pain and disability in chronic pain patients.³¹–³⁶

Although not evaluated in our study, another important benefit of 10 kHz SCS is the absence of uncomfortable stimulation arising from postural changes, enabling patients to carry out routine daily activities with a high level of comfort. Around 95% of 10 kHz SCS patients in the SENZA-RCT reported driving and sleeping with stimulation switched on.¹⁹ Stauss et al.²⁷ corroborated this finding in their large retrospective study. In contrast, less than two-thirds of traditional SCS patients in the SENZA-RCT indicated being able to do the same,¹⁸,¹⁹ and almost half reported uncomfortable stimulation.¹⁷ Being able to drive and sleep with minimal pain and discomfort are meaningful everyday aspects for patients. Driving is especially crucial for those who wish to return to work after treatment.

Overall, the present study showed promising outcomes in this group of Dutch FBSS patients with predominant radicular symptoms. To our knowledge, this study is the first to evaluate 10 kHz SCS in this patient group. However, our study lacked a control group and randomization, which could lead to selection bias in the patient population. Moreover, the study enrolled patients with predominant leg pain, and the patients also had back pain albeit with comparatively less intensity. The study could not isolate the patients who had only leg pain because the majority of FBSS patients have back pain along with leg pain with varying intensity. However, in all subjects, leg pain was the predominant complaint following back surgery. Consequently, our results should be interpreted within this context.

**CONCLUSIONS**

Failed back surgery syndrome is a complex pathology that leaves patients with chronic back and/or radicular pain that is often refractory to conventional treatment. The present study prospectively evaluated 10 kHz SCS in FBSS patients with predominant leg pain and found the treatment to be safe and effective. The findings demonstrate that 10 kHz SCS may be a useful therapeutic option to treat the diverse range of back and leg pain symptoms experienced by FBSS patients.

**ACKNOWLEDGEMENTS**

Anja Schaeken and Wim Laloo were involved in design, project setup, and management. Deborah Edgar Ph.D., Commexus Ltd, U.K., prepared the manuscript in her capacity as an independent medical writer. For this
service, she received a fee from Nevro Corp., Redwood City, CA, USA.

CONFLICT OF INTERESTS

J.K.W. is a consultant for Nevro Corp. A.R., A.S., D.C., J.S., P.R., and V.M. are employees of Nevro Corp. Rest of the authors have no conflicts to disclose.

REFERENCES

1. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study. GBD 2016 disease and injury incidence and prevalence collaborators. Lancet. 2017;390:1211–1259.

2. Hurwitz EL, Randhawa K, Yu H, Cote P, Haldeman S. The global spine care initiative: a summary of the global burden of low back and neck pain studies. Eur Spine J. 2018;27:796–801.

3. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858.

4. Steiger HJ, Kramer M, Reulen HJ. Development of neurosurgery in Germany: comparison of data collected by polls for 1997, 2003, and 2008 among providers of neurosurgical care. World Neurosurg. 2012;77:18–27.

5. Rajaee SS, Bae HW, Kanim LE, Delamarter RB. Spinal fusion in the United States: analysis of trends from 1998 to 2008. Spine. 2012;37:67–76.

6. Sivasubramaniam V, Patel HC, Ozdemir BA, Papadopoulos MC. Trends in hospital admissions and surgical procedures for degenerative lumbar spine disease in England: a 15-year time-series study. BMJ Open. 2015;5:e009011.

7. Grotle M, Smastuen MC, Fjeld O, et al. Lumbar spine surgery across 15 years: trends, complications and reoperations in a longitudinal observational study from Norway. BMJ Open. 2019;9:e028743.

8. Martin BI, Mirza SK, Spina N, Spiker WR, Lawrence B, Brodke DS. Trends in lumbar fusion procedure rates and associated hospital costs for degenerative spinal diseases in the United States, 2004 to 2015. Spine. 2019;44:369–376.

9. Parker SL, Mendenhall SK, Godil SS, et al. Incidence of low back pain after lumbar discectomy for herniated disc and its effect on patient-reported outcomes. Clin Orthop Relat Res. 2015;473:1988–1999.

10. Weir S, Samnaliev M, Kuo TC, et al. The incidence and healthcare costs of persistent postoperative pain following lumbar spine surgery in the UK: a cohort study using the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). BMJ Open. 2017;7:e017585.

11. Thomson S, Jacques L. Demographic characteristics of patients with severe neuropathic pain secondary to failed back surgery syndrome. Pain Pract. 2009;9:206–215.

12. North RB, Kidd DH, Farrokhj F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery. 2005;56:98–106; discussion 106-107.

13. Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain. 2007;132:179–188.

14. Kumar K, Taylor RS, Jacques L, et al. The effects of spinal cord stimulation in neuropathic pain are sustained: a 24-month follow-up of the prospective randomized controlled multicentre trial of the effectiveness of spinal cord stimulation. Neurosurgery. 2008;63:762–770; discussion 770.

15. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol. 2007;14:952–970.

16. National Institute for Health and Clinical Excellence (NICE). Spinal Cord Stimulation for Chronic Pain of Neuropathic or Ischaemic Origin (TA159). London, UK: National Institute for Health and Clinical Excellence (NICE); 2008.

17. Kapural L, Yu C, Doust MW, et al. Novel 10-kHz high-frequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: the SENZA-RCT randomized controlled trial. Anesthesiology. 2015;123:851–860.

18. Kapural L, Yu C, Doust MW, et al. Comparison of 10-kHz high-frequency and traditional low-frequency spinal cord stimulation for the treatment of chronic back and Leg pain: 24-month results from a multicenter, randomized, controlled pivotal trial. Neurosurgery. 2016;79:667–677.

19. Amirdelfan K, Yu C, Doust MW, et al. Long-term quality of life improvement for chronic intractable back and leg pain patients using spinal cord stimulation: 12-month results from the SENZA-RCT. Qual Life Res. 2018;27:2035–2044.

20. Van Buyten JP, Al-Kaisy A, Smet I, Palmisani S, Smith T. High-frequency spinal cord stimulation for the treatment of chronic back pain patients: results of a prospective multicenter European clinical study. Neuromodulation. 2013;16:59–65; discussion 65–56.

21. Al-Kaisy A, Van Buyten JP, Smet I, Palmisani S, Pang D, Smith T. Sustained effectiveness of 10 kHz high-frequency spinal cord stimulation for patients with chronic, low back pain: 24-month results of a prospective multicenter study. Pain Med. 2014;15:347–354.

22. Rapcan R, Mlaka J, Venglarick M, Vinklerova V, Gajdos M, Illes R. High-frequency – spinal cord stimulation. Bratisl Med J. 2015;116:354–356.

23. Al-Kaisy A, Royds J, Al-Kaisy O, et al. Cascade programming for 10 kHz spinal cord stimulation: a single center case series of 114 patients with neuropathic back and leg pain. Neuromodulation. 2020.
24. Dowell D, Compton WM, Giroir BP. Patient-centered reduction or discontinuation of long-term opioid analgesics: the HHS guide for clinicians. *JAMA*. 2019;1–3.

25. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA*. 2016;315:1624–1645.

26. Sayed D, Kallewaard JW, Rotte A, Jameson J, Caraway D. Pain relief and improvement in quality of life with 10 kHz SCS therapy: summary of clinical evidence. *CNS Neurosci Ther.* 2020;26:403–415.

27. Stauss T, El Majdoub F, Sayed D, et al. A multicenter real-world review of 10 kHz SCS outcomes for treatment of chronic trunk and/or limb pain. *Ann Clin Transl Neurol.* 2019;6:496–507.

28. Gharibo C, Laux G, Forzani BR, Sellars C, Kim E, Zou S. State of the field survey: spinal cord stimulator use by academic pain medicine practices. *Pain Med.* 2014;15:188–195.

29. Moore DM, McCrory C. Spinal cord stimulation. *BJA Educ.* 2016;16:258–263.

30. DiBenedetto DJ, Wawrzyniak KM, Schatman ME, Kulich RJ, Finkelman M. 10 kHz spinal cord stimulation: a retrospective analysis of real-world data from a community-based, interdisciplinary pain facility. *J Pain Res.* 2018;11:2929–2941.

31. Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. *Psychosom Med.* 2008;70:890–897.

32. Lerman SF, Rudich Z, Brill S, Shalev H, Shahar G. Longitudinal associations between depression, anxiety, pain, and pain-related disability in chronic pain patients. *Psychosom Med.* 2015;77:333–341.

33. Tsuji T, Matsudaira K, Sato H, Vietri J. The impact of depression among chronic low back pain patients in Japan. *BMC Musculoskelet Disord.* 2016;17:447.

34. Meints SM, Edwards RR. Evaluating psychosocial contributions to chronic pain outcomes. *Prog Neuropsychopharmacol Biol Psychiatry.* 2018;87:168–182.

35. Wertli MM, Eugster R, Held U, Steurer J, Kofmehl R, Weiser S. Catastrophizing-a prognostic factor for outcome in patients with low back pain: a systematic review. *Spine J.* 2014;14:2639–2657.

36. Martinez-Calderon J, Jensen MP, Morales-Asencio JM, Luque-Suarez A. Pain Catastrophizing and function in individuals with chronic musculoskeletal pain: a systematic review and meta-analysis. *Clin J Pain.* 2019;35:279–293.